Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface. The company was founded in 2004 and is based in Isfiya, Israel.
Industry, Sector and Symbol
Industry X-ray apparatus & tubes
Sub-IndustryN/A
SectorMedical
Phone972-4830-3401
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees48
OptionableNot Optionable
Check Cap (NASDAQ:CHEK) Frequently Asked Questions
What is Check Cap's stock symbol?
Check Cap trades on the NASDAQ under the ticker symbol "CHEK."
When did Check Cap's stock split? How did Check Cap's stock split work?
Shares of Check Cap reverse split on Wednesday, April 4th 2018. The 1-12 reverse split was announced on Wednesday, April 4th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 3rd 2018. An investor that had 100 shares of Check Cap stock prior to the reverse split would have 8 shares after the split.
How were Check Cap's earnings last quarter?
Check Cap Ltd (NASDAQ:CHEK) posted its quarterly earnings data on Monday, November, 5th. The medical research company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.03. View Check Cap's Earnings History.
When is Check Cap's next earnings date?
What price target have analysts set for CHEK?
1 equities research analysts have issued twelve-month price targets for Check Cap's stock. Their forecasts range from $14.00 to $14.00. On average, they expect Check Cap's share price to reach $14.00 in the next twelve months. This suggests a possible upside of 405.4% from the stock's current price. View Analyst Price Targets for Check Cap.
What is the consensus analysts' recommendation for Check Cap?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Check Cap in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Check Cap.
What are Wall Street analysts saying about Check Cap stock?
Here are some recent quotes from research analysts about Check Cap stock:
- 1. According to Zacks Investment Research, "Check Cap Ltd. is a medical diagnostics company. The company is engaged in the development of an ingestible imaging capsule for the screening of colorectal cancer. Check Cap Ltd. is based in Mount Carmel, Israel. " (1/3/2019)
- 2. HC Wainwright analysts commented, "We note that these results compare favorably to those released from the CE Mark study, as C-Scan system version 3 has better scan imaging density, 2D/3D imaging and a new motility analysis algorithm. Management expects to report final results on a larger patient group in 2Q19. Given the encouraging interim data, we continue to believe that C-Scan could be commercially launched in EU through a partner in 2019. Check-Cap has already applied to register C-Scan for marketing and sale in Israel, and marketing approval in Israel could be obtained in the current quarter, in our view. We believe C-Scan has the potential to increase the number of adults screened for CRC by eliminating common barriers such as unpleasant bowel preparation, and allow for early detection of polyps without the use of colonoscopy. In the wake of this update, we reiterate our Buy rating and $14 price target." (9/5/2018)
Has Check Cap been receiving favorable news coverage?
Headlines about CHEK stock have been trending somewhat negative this week, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Check Cap earned a news impact score of -1.4 on InfoTrie's scale. They also gave news coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future.
Who are some of Check Cap's key competitors?
Some companies that are related to Check Cap include 22nd Century Group (XXII), 3D Signatures (DXD), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abaxis (ABAX), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acerus Pharmaceuticals (ASP), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Actinogen Medical (ACW) and Activecare (ACAR).
Who are Check Cap's key executives?
Check Cap's management team includes the folowing people:
- Mr. Alex Ovadia, CEO & Director (Age 56)
- Mr. William Densel, Chief Exec. Officer (Age 50)
- Dr. Yoav Kimchy, Founder & Chief Technology Officer (Age 57)
- Mr. Lior Torem, Chief Financial Officer (Age 48)
- Boaz Shpigelman, VP of R&D (Age 46)
When did Check Cap IPO?
(CHEK) raised $13 million in an IPO on Thursday, February 19th 2015. The company issued 1,200,000 shares at a price of $10.00-$12.00 per share. Chardan Capital Markets and Maxim Group acted as the underwriters for the IPO and Feltl and Company was co-manager.
How do I buy shares of Check Cap?
Shares of CHEK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Check Cap's stock price today?
One share of CHEK stock can currently be purchased for approximately $2.77.
What is Check Cap's official website?
How can I contact Check Cap?
Check Cap's mailing address is 29 ABBA HUSHI AVE. P.O.BOX 1271, ISFIYA L3, 3009000. The medical research company can be reached via phone at 972-4830-3401.
MarketBeat Community Rating for Check Cap (NASDAQ CHEK)
MarketBeat's community ratings are surveys of what our community members think about Check Cap and other stocks. Vote "Outperform" if you believe CHEK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CHEK will underperform the S&P 500 over the long term. You may vote once every thirty days.
